Combining Molecularly Targeted Agents: Is More Always Better?

Abstract

The concurrent targeting of critical nodes along key signaling pathways with molecularly targeted agents is a rational antitumor strategy, which has had varying degrees of success. Combinatorial challenges include overcoming synergistic toxicities and establishing whether combinations are truly active, to make "go, no-go" decisions to proceed to later phase trials. Clin Cancer Res; 23(5); 1123-5. ©2016 AACRSee related article by Calvo et al., p. 1177.